Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Pierre Gotteland

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
Reproductive Sciences (Thousand Oaks, Calif.)|March 8, 2014
Synergistic effects of E2MATE and norethindrone acetate on steroid sulfatase inhibition: a randomized phase I proof-of-principle clinical study in women of reproductive ageOliver Pohl, Elke Bestel, Jean-Pierre Gotteland
Reproductive Sciences (Thousand Oaks, Calif.)|September 18, 2014
The clinical pharmacology and pharmacokinetics of ulipristal acetate for the treatment of uterine fibroidsOliver Pohl, R Howard Zobrist, Jean-Pierre Gotteland
International Journal of Clinical Pharmacology and Therapeutics|November 1, 2012
Changes in gastric pH and in pharmacokinetics of ulipristal acetate - a drug-drug interaction study using the proton pump inhibitor esomeprazoleOliver Pohl, Ian Osterloh, Véronique Lecomte, et al.
Reproductive Sciences (Thousand Oaks, Calif.)|February 27, 2020
Effects of combined GnRH receptor antagonist linzagolix and hormonal add-back therapy on vaginal bleeding-delayed add-back onset does not improve bleeding patternOliver Pohl, Line Marchand, David Bell, et al.
Therapeutic Innovation & Regulatory Science|February 3, 2020
Efficient Design of Integrated and Adaptively Interlinked Protocols for Early-Phase Drug Development ProgramsSimon Coates, Oliver Pohl, Jean-Pierre Gotteland, et al.
The Journal of Clinical Endocrinology and Metabolism|December 8, 2017
Gonadotropin-Releasing Hormone Receptor Antagonist Mono- and Combination Therapy With Estradiol/Norethindrone Acetate Add-Back: Pharmacodynamics and Safety of OBE2109Oliver Pohl, Line Marchand, Neil Fawkes, et al.
Regulatory Toxicology and Pharmacology : RTP|March 12, 2013
A 39-week oral toxicity study of ulipristal acetate in cynomolgus monkeysOliver Pohl, Alistair R W Williams, Christine Bergeron, et al.
Endocrinology|January 9, 2010
Kit ligand and the somatostatin receptor antagonist, BIM-23627, stimulate in vitro resting follicle growth in the neonatal mouse ovaryAlain Gougeon, Aurélien Delangle, Nassim Arouche, et al.
British Journal of Clinical Pharmacology|March 21, 2019
Coadministration of the prostaglandin F2α receptor antagonist preterm labour drug candidate OBE022 with magnesium sulfate, atosiban, nifedipine and betamethasoneOliver Pohl, Line Marchand, Jean-Pierre Gotteland, et al.
British Journal of Clinical Pharmacology|December 14, 2021
A model-based analysis to guide gonadotropin-releasing hormone receptor antagonist use for management of endometriosisOliver Pohl, Kyle Baron, Matthew Riggs, et al.
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
Reproductive Sciences (Thousand Oaks, Calif.)|March 8, 2014
Synergistic effects of E2MATE and norethindrone acetate on steroid sulfatase inhibition: a randomized phase I proof-of-principle clinical study in women of reproductive ageOliver Pohl, Elke Bestel, Jean-Pierre Gotteland
Reproductive Sciences (Thousand Oaks, Calif.)|September 18, 2014
The clinical pharmacology and pharmacokinetics of ulipristal acetate for the treatment of uterine fibroidsOliver Pohl, R Howard Zobrist, Jean-Pierre Gotteland
International Journal of Clinical Pharmacology and Therapeutics|November 1, 2012
Changes in gastric pH and in pharmacokinetics of ulipristal acetate - a drug-drug interaction study using the proton pump inhibitor esomeprazoleOliver Pohl, Ian Osterloh, Véronique Lecomte, et al.
Reproductive Sciences (Thousand Oaks, Calif.)|February 27, 2020
Effects of combined GnRH receptor antagonist linzagolix and hormonal add-back therapy on vaginal bleeding-delayed add-back onset does not improve bleeding patternOliver Pohl, Line Marchand, David Bell, et al.
Therapeutic Innovation & Regulatory Science|February 3, 2020
Efficient Design of Integrated and Adaptively Interlinked Protocols for Early-Phase Drug Development ProgramsSimon Coates, Oliver Pohl, Jean-Pierre Gotteland, et al.
The Journal of Clinical Endocrinology and Metabolism|December 8, 2017
Gonadotropin-Releasing Hormone Receptor Antagonist Mono- and Combination Therapy With Estradiol/Norethindrone Acetate Add-Back: Pharmacodynamics and Safety of OBE2109Oliver Pohl, Line Marchand, Neil Fawkes, et al.
Regulatory Toxicology and Pharmacology : RTP|March 12, 2013
A 39-week oral toxicity study of ulipristal acetate in cynomolgus monkeysOliver Pohl, Alistair R W Williams, Christine Bergeron, et al.
Endocrinology|January 9, 2010
Kit ligand and the somatostatin receptor antagonist, BIM-23627, stimulate in vitro resting follicle growth in the neonatal mouse ovaryAlain Gougeon, Aurélien Delangle, Nassim Arouche, et al.
British Journal of Clinical Pharmacology|March 21, 2019
Coadministration of the prostaglandin F2α receptor antagonist preterm labour drug candidate OBE022 with magnesium sulfate, atosiban, nifedipine and betamethasoneOliver Pohl, Line Marchand, Jean-Pierre Gotteland, et al.
British Journal of Clinical Pharmacology|December 14, 2021
A model-based analysis to guide gonadotropin-releasing hormone receptor antagonist use for management of endometriosisOliver Pohl, Kyle Baron, Matthew Riggs, et al.
Pageof 4